| 2025 | 2024 | 2023 | 2022 | |||||
|---|---|---|---|---|---|---|---|---|
| Gross margin | -12,1 k € | +55.5% | -27,2 k € | +71.8% | -96,3 k € | +40.1% | -160,7 k € | |
| EBITDA | -12,6 k € | +55.3% | -28,3 k € | +70.8% | -96,8 k € | +40.1% | -161,7 k € | |
| Operating profit | -78,2 k € | +62.8% | -209,9 k € | +74.2% | -812,9 k € | +51.1% | -1,7 M € | |
| Profit/loss | -89,9 k € | +43.2% | -158,1 k € | +79.6% | -773,9 k € | +52.8% | -1,6 M € | |
| Equity | -60,0 k € | -301.2% | 29,8 k € | -84.1% | 188,0 k € | -80.5% | 961,9 k € | |
| Total assets | 166,1 k € | -33.4% | 249,5 k € | -4.5% | 261,2 k € | -73.2% | 973,2 k € | |
| Cash | 23,3 k € | -44.6% | 42,1 k € | -47.9% | 81,0 k € | -89.6% | 778,6 k € | |
| Debts | 226,1 k € | +3.0% | 219,7 k € | +200.1% | 73,2 k € | +547.9% | 11,3 k € | |
Public limited company · Gent · incorporated on 12/07/2021
Public limited company loss-making in the latest fiscal year. Cash position declining (-44.6%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
Jay Therapeutics is a Public limited company incorporated in 2021. Its main activity is: Research and experimental development on natural sciences and engineering. Its registered office is in Gent.
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette